Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid Leukemia

Seminars in Hematology

Volumn 46, Issue SUPPL. 3, 2009, Pages

  Jabbour, Elias ^a   Soverini, Simona ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 AMINO 5 (4 METHYLPHENYL) 7 (T BUTYL)PYRAZOLO 3,4 DEXTRO PYRIMIDINE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; IMATINIB; NILOTINIB; OMACETAXINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 63249086307     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.01.009     Document Type: Article

References (43)

1. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
2. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306 (1983) 277-280
3. Nardi V., Azam M., and Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11 (2004) 35-43
4. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
5. Soverini S., Martinelli G., Colarossi S., Gnani A., Castagnetti F., Rosti G., et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24 (2006) e51-e52
6. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007) 1018-1029
7. Corbin A.S., La Rosee P., Stoffregen E.P., Druker B.J., and Deininger M.W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
8. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
9. Kantarjian H., Schiffer C., Jones D., and Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111 (2008) 1774-1780
10. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
11. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
12. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006) 7374-7379
13. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
14. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
15. Cortes J., Jabbour E., Kantarjian H., Yin C.C., Shan J., O'Brien S., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
16. Jabbour E., Kantarjian H.M., Jones D., Reddy N., O'Brien S., Garcia-Manero G., et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112 (2008) 4839-4842
17. Nicolini F.E., Hayette S., Corm S., Bachy E., Bories D., Tulliez M., et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 92 (2007) 1238-1241
18. Jabbour E., Kantarjian H., Jones D., Breeden M., Garcia-Manero G., O'Brien S., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008) 53-55
19. Jabbour E., Kantarjian H., Atallah E., Borthakur G., Wierda W., Faderl S., et al. Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML). Blood 110 (2007) 313a-314a
20. Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood (2008) Dec 5. [Epub ahead of print]
21. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-6661
22. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
23. Golemovic M., Verstovsek S., Giles F., Cortes J., Manshouri T., Manley P.W., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 (2005) 4941-4947
24. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
25. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
26. Radich J., Kim D., Martinelli G., Branford S., Mueller M., Haque A., et al. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline. Haematologica 93 (2008) 21
27. Saglio G., Radich J., Kim D., Martinelli G., Branford S., Mueller M., et al. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline. J Clin Oncol 26 (2008) 387s
28. Hochhaus A., Mueller M., Cortes J.E., Kim D., Matloub Y., Ploughman L., et al. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure. J Clin Oncol 26 May 20 suppl (2008) 375s
29. Hochhaus A., Müller M.C., Cortes J.E., Kim D.W., Matloub Y., Ploughman L., et al. Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 93 Suppl 1 (2008) 371-372
30. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32 (2008) 980-983
31. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 102 (2005) 3395-3400
32. Puttini M., Coluccia A.M., Boschelli F., Cleris L., Marchesi E., Donella-Deana A., et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66 (2006) 11314-11322
33. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 (2005) 3948-3954
34. O'Hare T., Pollock R., Stoffregen E.P., Keats J.A., Abdullah O.M., Moseson E.M., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104 (2004) 2532-2539
35. Warmuth M., Simon N., Mitina O., Mathes R., Fabbro D., Manley P.W., et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101 (2003) 664-672
36. Marin D., Maloisel F., Legros L., Nicolini F.E., Roy L., and Rousselot P. Efficacy of subcutaneous homoharringtonine in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors and harboring a BCR-ABL mutation. Haematologica 93 s1 (2008) 56
37. Cortes J.C., Khoury J., Corm S., Nicolini F.E., Benichou A.C., Craig A.R., et al. Data from a multicenter open label study of subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients with T315I mutation. Haematologica 93 Suppl 1 (2008) 48-49
38. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 (2007) 500-502
39. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 (2005) 11011-11016
40. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology. Chronic myelogenous leukemia (2009) © 2006 National Comprehensive Cancer Network, Inc. Version 2. Jenkintown, PA
41. Willis S.G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
42. Khorashad J.S., Anand M., Marin D., Saunders S., Al-Jabary T., Iqbal A., et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20 (2006) 658-663
43. Sherbenou D.W., Wong M.J., Humayun A., McGreevey L.S., Harrell P., Yang R., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21 (2007) 489-493